Objective-Inappropriate transcriptional activation of innate immunity is a pathological feature of several cardiometabolic disorders, but little is known about inflammatory modulation of long intergenic noncoding RNAs (lincRNAs) in diseaserelevant human tissues. Approach and Results-We applied deep RNA sequencing (>500 million filtered reads per sample) to blood and adipose during low-dose experimental endotoxemia (lipopolysaccharide) in a healthy human, with targeted replication in separate individuals undergoing endotoxemia (n=6), to identify inflammatory lincRNAs. A subset of these lincRNAs was examined for expression in adipocytes and monocytes, modulation in adipose of obese humans, and overlap with genome-wide association study signals for inflammatory and cardiometabolic traits. Of a stringent set of 4284 lincRNAs, ≈11% to 22% were expressed with 201 and 56 lincRNAs modulated by lipopolysaccharide in blood or adipose, respectively. Tissuespecific expression of a subset of 6 lipopolysaccharide-lincRNAs was replicated with lipopolysaccharide modulation confirmed for all 3 expressed in blood and 2 of 4 expressed in adipose. The broader generalizability of findings in blood of subject A was confirmed by RNA sequencing in 7 additional subjects. We confirmed adipocytes and monocytes as potential cell-sources of selective lipopolysaccharide-regulated lincRNAs, and 2 of these, linc-DMRT2 (P=0.002) and linc-TP53I13 (P=0.01), were suppressed in adipose of obese humans. Finally, we provide examples of lipopolysaccharidemodulated lincRNAs that overlap single nucleotide polymorphisms that are associated with cardiometabolic traits. Conclusions-Our findings provide novel insights into tissue-level, inflammatory transcriptome regulation in cardiometabolic diseases. These are complementary to more usual approaches limited to interrogation of DNA variations.
A portion of the genetic basis of complex diseases is apparent from recent genome-wide association studies (GWASs). However, it is evident that scanning the genome can identify only a portion of the genomic influence on many heritable disorders. 1 Transcriptomics provides a promising avenue for a more complete understanding of the functional elements of the genome that mediate tissue-specific disease manifestations. Indeed, the advent of high-throughput RNA sequencing (RNA-seq) has demonstrated the existence of a far greater and tissue-specific transcriptomic complexity than that of previously estimated. [2] [3] [4] [5] [6] [7] The conventional view of the genome as simply containing structural and protein-coding genes is evolving rapidly with the realization of the diversity of RNA species in mammalian cells. [4] [5] [6] 8 Regions previously thought to be silent are transcribed into a wide-range of functional transcripts broadly known as noncoding RNAs (ncRNAs). One class of such ncRNAs loosely known as long (>200 nt) ncRNAs (lncRNAs) are distinct from more studied microRNAs and as yet are poorly understood. [5] [6] [7] Although debate continues on the proportion of lncRNAs that are likely to be functional, 6, 7 many have mRNA-like features (eg, polyA tail and exons/introns), 7 and several important examples have critical functions in cell biology (eg, the cis-regulatory Xist, 9 Hotair, 10 and Mistral) 11 including ANRIL, 12 the likely causal transregulatory gene at the common 9p21 vascular disease locus. Because lncRNAs are poorly characterized in terms of evolution, conservation, secondary structure, and functions, 5, 7 there is a dearth of understanding of lncRNAs in human physiology and disease. To simplify their study separately from other RNA species, recent focus often has been on the subset of lncRNAs known as long intergenic (or intervening) lncRNA (ie, long intergenic noncoding RNA [lincRNAs]) that do not overlap with exons of protein-coding genes. 5, 7, 8 Inappropriate and sustained tissue-specific transcriptional activation of innate immunity by diet and lifestyle factors in genetically prone individuals is a pathological feature of several cardiometabolic disorders, including atherosclerosis, obesity, and insulin resistance. Although early data on lncRNA modulation during activation of innate immunity are emerging, 13, 14 little is known on human cells and tissues. We use low-dose experimental endotoxemia (lipopolysaccharide) to activate toll-like receptor 4 (TLR4) signaling in humans as a model to study in vivo inflammatory cardiometabolic responses. [15] [16] [17] [18] [19] [20] Epidemiological, 21, 22 clinical, 23 and experimental 19 studies in human, as well as disease modeling in rodents, 24 support the relevance of this model. In our previous studies, we reported endotoxemia-induced metabolic dyslipidemia 18 and systemic insulin resistance 19 coincident with adipose inflammation. 19, 25 Previous studies also suggest cell-specific transcriptome 16, 25 modulation, at least of protein-coding genes, during endotoxemia.
Recently, a reciprocal pattern of inflammatory lincRNA induction with subsequent negative feedback on immune signaling has been described, 13, 14 suggesting a functional role of specific lincRNAs in regulating innate immunity. Here, we applied very-deep RNA-seq to whole blood and adipose during experimental endotoxemia (lipopolysaccharide, 1 ng/kg intravenous bolus) in a participant enrolled in the Genetics of Evoked-responses to Niacin and Endotoxemia (GENE) study, 26 with targeted replication in additional GENE subjects, to identify inflammatory lincRNAs that may modulate complex cardiometabolic disorders. We report novel tissue-specific, inflammatory regulation of specific lincRNAs, examine their genomic features, probe potential cellular origins, and explore their potential relevance in human cardiometabolic diseases.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Overview, Clinical Characteristics, and RNA-Seq Data Alignment and Filtering
An overview of study design and results is shown in Figure 1 . The GENE study is a single-center University of Pennsylvaniabased National Institutes of Health-sponsored endotoxemia protocol (n=284; 33% blacks; age, 18-45 years; NIH.gov clinical trial NCT00953667). 26 Whole blood RNA samples were collected at baseline and multiple time points after lipopolysaccharide. Gluteal subcutaneous fat tissue was biopsied and snap-frozen before and after lipopolysaccharide as described. 19, 25 In this report, we focus initially on a self-reported European Ancestry individual (subject A) for deep RNA-seq. To enrich discovery, subject A was chosen from those with above-median inflammatory response (Tables 1 and 2 ). Our primary analysis was of whole blood and adipose RNA-seq data; RNA-seq data were generated also in peripheral blood mononuclear cells (PBMCs) to compare the findings of whole blood data. Selective lipopolysaccharide-modulated events in blood and adipose of subject A were assessed for replication in independent GENE participants (n=6; subjects B-G) also chosen from those with above-average inflammatory response (Tables 1 and 2 ). The broader generalizability of findings in subject A was examined by RNA-seq in 7 additional GENE subjects ( Table I in We obtained 1400 million (M)/976 M reads and 912/1040 M reads for the pre-/postlipopolysaccharide blood and adipose samples, respectively. The data were aligned and filtered as described in Materials and Methods in the online-only Data Supplement. We obtained a high mapping rate with 95% and 98% of reads mapped to the reference genome for pre-and postlipopolysaccharide blood samples and 85% and 82% of reads pre-and postlipopolysaccharide adipose samples. Of these, 60% and 63% of reads in blood and 53% and 49% of reads in adipose were uniquely mapped and properly filtered ( Table IIA in the online-only Data Supplement). For all blood RNA-seq samples (subject A and others), we eliminated hemoglobin gene sequences (located on chromosomes 11 and 16) because these sequences are uninformative (for lipopolysaccharide modulation) yet dominate the blood RNA-seq data because of their high abundance. In our analysis, we only considered reads from autosomal and sex chromosomes, and this left 586/881 M filtered reads for pre-/postlipopolysaccharide blood samples and 482/505 M filtered reads for pre-/postlipopolysaccharide adipose samples, respectively. For ease of notation, we denote these 4 data sets as 500 M RNA-seq data. In lower depth RNA-Seq of subject A, we obtained 116/138 M and 67/65 M reads for the pre-/postlipopolysaccharide blood and adipose samples, respectively (≈50 M or low RNA-seq Table 1 
. Clinical Characteristics of Study Subjects (A-G) and all Genetics of Evoked-Responses to Niacin and Endotoxemia Study European Ancestry Participants at Baseline
RNA-Seq of LincRNAs in Blood and Adipose
To limit spurious findings, we focused on the stringent subset of 4284 lincRNAs with ≥1 isoform reconstructed in ≥2 human tissues or by 2 assemblers in the same tissue from the full data set of 8179 lincRNAs identified through RNA-seq by Cabili et al. 8 For consistency across tissues, we included lincRNAs that were expressed at FPKM>0.
Sequencing Depth for Analysis of Human LincRNAs
Recently, we analyzed sequencing depth requirements for detection of differentially expressed (DE) protein-coding genes in human adipose and found that substantially greater depth was required to detect DE than to detect simple basal expression. 27 Because expression of lincRNAs is generally lower than protein-coding genes, our first step was to determine the sequence depth required to assess DE by empirical evaluations (eg, lipopolysaccharide modulation). Briefly, treating the 500 M adipose data sets as the gold standard, we evaluated percentages of expressed lincRNAs and DE lin-cRNAs detected at lower sequencing depths (using randomly selected reads with incrementally lower sequencing depths). Although ≈75% of expressed lincRNAs can be detected at sequencing depths of 300 M, we found that 400 M read-depth was required to detect DE and even higher depth to detect DE of lincRNAs with lower expression (eg, 450 M depth for lincRNAs <25th percentile expression; Figure I in the online-only Data Supplement). Thus, our deeply sequenced 500 M data sets provided substantial depth for detection of DE lincRNAs even for those with low expression. By contrast, in subject A low-depth RNA-seq replicates, only 13% of DE lincRNAs were detected in adipose relative to 500 M data.
LincRNA Expression in Blood and Adipose
Of the 4284 human lincRNAs, ≈22% were expressed (at FPKM>0 and OK status in cuffdiff analysis) 28 in blood and ≈11% in adipose of 500 M subject A samples; 931 and 453, respectively, before lipopolysaccharide and 894 and 445, respectively, after lipopolysaccharide. In the low-depth RNA-seq data for subject A, only 409 and 402 and 101 and 100 lincRNAs were expressed before and after lipopolysaccharide in blood and adipose, respectively. For protein-coding genes, we detected 14 564 and 11 464, respectively, before lipopolysaccharide and 14 521 and 11 418, respectively, after lipopolysaccharide in blood and adipose.
Cabili et al 8 and others [5] [6] [7] suggest that human lincRNAs have more tissue-specific expression than protein-coding genes. For lincRNAs and protein-coding mRNAs expressed in either blood or adipose of subject A, we counted the number that overlapped between the 2 tissues ( Figure 2 ). Among 931 in blood and 453 lincRNAs in adipose before lipopolysaccharide, 251 overlapped (27% for blood and 55% for adipose; Figure 2A ). Of 894 lincRNAs in blood and 445 in adipose after lipopolysaccharide, 235 overlapped (26% for blood and 53% for adipose). When compared with protein-coding genes ( Figure 2B ), the percentages of blood-adipose overlapping lincRNAs were significantly lower (eg, prelipopolysaccharide blood, 27% versus 73%; Fisher exact test, P<2.2×10 -16 and adipose 55% versus 89%, P<2.2×10 -16 ), suggesting greater tissue specificity for lincRNAs than protein-coding genes. The differences were less pronounced but still significant when analysis was restricted to protein-coding genes with low expression levels, similar to lincRNAs (eg, before lipopolysaccharide, blood 27% versus 55%; Fisher exact test, P<2.2×10 -16 and adipose 55% versus 61%; P=0.018).
Lipopolysaccharide Modulation of lincRNAs
In subject A, we detected a modest number of lipopolysaccharide-regulated lincRNAs, 201 and 56 in blood and adipose, respectively (Figure 2A ; Table IIIA and IIIB in the online-only Data Supplement). The majority was downregulated in both blood (n=150; 75%) and adipose (n=38; 68%). This pattern of greater lipopolysaccharide downregulation was similar to that for lipopolysaccharide-modulated protein-coding genes (n=1996; 72% in blood; n=3242; 93% in adipose, respectively) and is consistent with previous published data. 16 A B One concern when examining apparent lipopolysaccharide modulation of gene expression in tissues with mixed cell content (eg, whole blood) is that lipopolysaccharide modulation of lincRNAs might be because of change in cell composition rather than because of actual lipopolysaccharide regulation of lincRNA expression. 29, 30 We addressed this concern indirectly for whole blood findings by generating RNA-seq data before and after lipopolysaccharide in PBMCs of subject A at the same time points as the whole blood RNA-seq (before and 2 hours after lipopolysaccharide). If lipopolysaccharide-driven change in blood cell composition was the predominant basis for lipopolysaccharide modulation in whole blood, then we would expect much less lipopolysaccharide modulation of lin-cRNAs in the PBMC samples because of more homogenous, monocyte-rich, cell composition of PBMC. However, this was not the case. We observed lipopolysaccharide modulation of lincRNAs in PBMCs to a degree that was very similar to that observed in whole blood (18.4% and 21.6% in PBMCs and whole blood, respectively; Table IV in the online-only Data Supplement). Indeed, there was substantial overlap (81%, 82%, and 48%) of pre-and post-lipopolysaccharide lincRNA expression and lipopolysaccharide modulation, respectively, in PBMCs and whole blood.
In preliminary translation, we selected 6 lipopolysaccharide-regulated lincRNAs in subject A for validation by quantitative real-time polymerase chain reaction. These were chosen to represent a range of FPKM expression and statistical significance of lipopolysaccharide modulation, as well as the presence in blood, adipose, or both; 3 were expressed in blood and 4 were expressed in adipose. We confirmed tissue patterns of expression and validated the direction of lipopolysaccharide modulation for all 6 lincRNAs in subject A blood and adipose. (Figure 3i and 3ii ; Figure II in the online-only Data Supplement).
This same subset of lincRNAs was examined by quantitative real-time polymerase chain reaction for replication of lipopolysaccharide modulation in separate GENE study subjects (n=6; Tables 1 and 2). Tissue-specific expression was confirmed for these lincRNAs in all subjects, and the direction of lipopolysaccharide modulation replicated for 3 of 3 blood-lincRNAs (linc-ARFIP1-4, linc-CMC1-2, and linc-TP53I13) and 2 of 4 adipose lincRNAs (linc-DMRT2 and linc-POTED8; Figure 3iii ; Figure II in the online-only Data Supplement). This suggests generalizability of lipopolysaccharide modulation, particularly in blood, for a subset of lipopolysaccharide-regulated lincRNAs identified in subject A. 
Tissue Specificity of Lipopolysaccharide-Modulated lincRNAs
For subject A lipopolysaccharide-regulated lincRNAs ( Table  III in the online-only Data Supplement), there was minor overlap between blood and adipose (Figure 2A ; 10 lincRNAs; 5% of blood in adipose, 18% of adipose in blood; linc-TP53I13 and linc-POTED8; linc-ARIH2, linc-STIM2-1, linc-TACC3, linc-ACSL1-1, linc-HEATR2-2, linc-CCND1-4, lincCGNL1-2, and linc-TMEM105-2). This pattern of tissue specificity was generally similar to lipopolysaccharide-modulated protein-coding genes ( Figure 2B ). When compared with such protein-coding genes, the percentages of blood-adipose overlapping lipopolysaccharide-regulated lincRNAs were slightly lower (eg, 5% versus 18% of blood in adipose; Fisher exact test, P=3.7×10 -7 ), but similar when compared with a subset of lipopolysaccharide-modulated protein-coding genes with a similar (low) level of expression (eg, 5% versus 8% of blood in adipose; P=0. 14) . In support of tissue specificity of lipopolysaccharide-modulated lincRNAs, we found no correlation between blood and adipose in the degree of lipopolysaccharide modulation of all lincRNAs (expressed either as fold-change or absolute change; data not shown). Thus, lipopolysaccharide-regulated lincRNAs are tissue specific in a manner generally consistent with that observed for lipopolysaccharide-modulated protein-coding genes.
Generalizability of RNA-Seq Findings for lincRNAs
To address the broader generalizability of RNA-seq patterns in subject A, we generated ( Table I in the online-only Data Supplement) additional RNA-seq data in 7 additional GENE study participants ( Table IIB in the online-only Data Supplement) for the same time points before and after lipopolysaccharide in blood and compared findings with that in subject A. These analyses of additional subjects revealed (1) substantial overlap between detectable lincRNAs to that in subject A (≈94% and 93%) before and after lipopolysaccharide, respectively and (2) substantial overlap in lipopolysaccharide-modulated lincRNAs to that in subject A (≈79%; Table 3 ). These RNA-seq data provide support for the broader generalizability of lincRNA expression and lipopolysaccharide-modulation, despite the confounding influence of lower RNA-seq depth in the additional blood samples and an expected heterogeneity in lipopolysaccharide clinical and transcriptomic response across humans. 16, 26 
Conservation of Lipopolysaccharide-Regulated LincRNAs
Recent data suggest rapid evolution and limited sequence conservation of lincRNAs. 5, 8 This not only questions the functional importance for poorly conserved lincRNAs but also raises the possibility of functions not dependent on primary sequence. 7 Using primate phastCons scores from 46-way vertebrate genome alignment 31 (available in conservation track, UCSC genome browser; http://genome. ucsc.edu/), expressed lincRNAs were markedly less conserved than protein-coding genes, whereas, in adipose but not blood, lincRNAs were slightly more conserved than intergenic regions ( Figure III in the online-only Data Supplement). Lipopolysaccharide-regulated lincRNAs were not more conserved than non-lipopolysaccharide-regulated lincRNAs (data not shown).
Transcription Factor-Binding Sites of LincRNAs
We hypothesized that if lipopolysaccharide modulation of lin-cRNAs reflects evolutionary conserved functions downstream of canonical TLR4 signaling, then lipopolysaccharide-regulated (versus non-lipopolysaccharide-regulated lincRNAs) lin-cRNAs would more likely harbor upstream sequences with active promoters and that these sequences would be enriched for NFκB transcription factor binding. To test this hypothesis, we obtained the motifs that correspond to NFκB family members: NFκB1, NFκB2, RELA, RELB, and REL from the TRANSFAC database (version 2012.3). 32 Sequences encompassing 2.5-kb upstream and 300-bp downstream of a lin-cRNA's start site were searched for motif occurrences using Find Individual Motif Occurrences. 33 Motifs for NFκB1 were enriched in lipopolysaccharide-regulated lincRNAs in blood (Fisher exact test, P=0.005). We also calculated the number of motifs in the 2.8-kb region for each lincRNA that contained ≥1 motif. For the combination of all NFκB family transcription factors, lipopolysaccharide-regulated lincRNAs had more motifs than non-lipopolysaccharide-regulated lincRNAs in blood (1-sided 2-sample t test P=0.037).
Translational and Genetic Studies of Lipopolysaccharide-Regulated LincRNAs
Cell Source and Modulation in Obesity
For lipopolysaccharide-modulated lincRNAs selected for validation, we tested the expression in vitro in human celltypes (adipocytes, monocytes, and macrophages) that Table IIB in are functionally implicated in cardiometabolic diseases. Adipocytes expressed relatively high levels of several lin-cRNAs (linc-DMRT2, linc-SLC16A7, and linc-CMC1-2). Consistent with expression in both blood and adipose, linc-TP53I13 and linc-POTED8 were found in monocytes and macrophages, as well as in adipocytes ( Figure 4A ). Linc-ARFIP1-4 and linc-CMC1-2 were not expressed in monocytes, suggesting an alternative blood cell source (eg, platelets or neutrophils) for in vivo expression in blood.
We explored disease relevance in obesity of the 4 selected adipose-expressed lincRNAs, and found that linc-DMRT2 (P=0.002) and linc-TP53I13 (P=0.01) were downregulated in obese adipose ( Figure 4B ).
Overlap of Lipopolysaccharide-Modulated LincRNAs With GWAS Loci for Cardiometabolic Traits
To illustrate the potential for RNA-seq to reveal lincRNA that may underlie GWAS disease associations, we interrogated established SNPs for inflammatory and cardiometabolic traits using the National Human Genome Research Institute GWAS catalogue (http://www.genome.gov/gwastudies; Table V in the online-only Data Supplement) for their overlap with lipopolysaccharide-regulated lincRNAs. First, we identified overlap between linc-CEP110-13 (chr9: 120521860-120639328) and rs10115586, a single nucleotide polymorphism (SNP) in intron 1 of linc-CEP110-13 that is associated with N-glycosylation of immunoglobulin G. 34 Linc-CEP110-13 is lipopolysaccharide induced in adipose (P=0.0028; false discovery rate adjusted P=0.016; Table IIIB in the online-only Data Supplement) with a similar trend in blood (P=0.016; false discovery rate adjusted P=0.068). rs10115586 lies 79-kb downstream of TLR4, the lipopolysaccharide receptor, but is not in linkage disequilibrium (r 2 <0.2; http://www.sph.umich. edu/csg/abecasis/MACH/download/1000G.2012-03-14.html; 1000 genome data) with SNPs in TLR4. We also found overlap of linc-VWF (chr12: 6258940-6289931), with rs1558324 a SNP in intron 1 of linc-VWF that is associated with mean platelet volume (P=1.55×10 -21 ; Gieger et al 35 ), a biomarker of platelet function that predicts myocardial infarction. 36 A second SNP (rs7342306) near linc-VWF (912 bp 5′) had a strong signal for platelet count (P=4.29×10 -11 ; Gieger et al 35 ) . Linc-VWF is induced in adipose ( Table IIIB in the online-only Data Supplement) but not expressed in our blood RNA-seq data. Notably, these linc-VWF SNPs have no linkage disequilibrium (r 2 <0.2; Figure 5 ) with SNPs (eg, rs1063856 or rs1063857) in VWF (located ≈105-kb upstream) that are associated with circulating VWF levels 37 or with SNPs in CD9 that lies ≈20-kb 3′ of linc-VWF.
Discussion
The activation of innate immunity is a pathological feature of several cardiometabolic disorders. We used low-dose human endotoxemia to perform genome-wide discovery of inflammatory lincRNAs as candidates for complex diseases characterized by disturbance of innate immunity. We report substantial and tissue-specific change in the expression of blood and adipose lincRNAs, confirm monocytes, macrophages, and adipocytes as potential cell-sources for selective lipopolysaccharide-regulated lincRNAs. We provide evidence that some lipopolysaccharide-regulated adipose lincRNAs are expressed in adipocytes and suppressed in adipose of obese humans (linc-DMRT2 and linc-TP53I13). Finally, we found that lipopolysaccharide-induced linc-CEP110-13, which lies downstream of TLR4, contains a SNP associated with N-glycosylation of immunoglobulin G, 34 whereas linc-VWF, also lipopolysaccharide induced, harbors SNPs for platelet traits 35 that predict cardiovascular disease events. 36 Knowledge of lncRNA species and biology is emerging rapidly, but current classifications are likely to include diverse noncoding RNA subsets with distinct genomic, evolutionary, and functional characteristics. [5] [6] [7] [8] Many lincRNAs have basic mRNA-like features, and several important examples (eg, Xist, Hotair, and Mistral) have emerged with critical roles in cell differentiation, growth, and apoptosis. [9] [10] [11] It is likely that a lncRNA, ANRIL, is the causal gene at the 9p21 vascular disease locus. 38 Yet, it is probable that many lincRNAs lack function and bioinformatic strategies for identifying functionality Figure 5 . A, Genome browser view and linkage disequilibrium plot for the chromosome 12 linc-von Willebrand factor (VWF) and VWF regions in European Ancestry (B). Highlighted linc-VWF single nucleotide polymorphisms (rs1558324 and rs7342306) have genome-wide association with platelet traits in Gieger et al. 35 are deficient. 7 Thus, there is limited knowledge of lincRNA regulation in human tissues or their role in human disease.
We found that the majority of lincRNAs, as well as protein-coding RNAs, were downregulated in blood and adipose by lipopolysaccharide. Although this is a novel finding for lincRNAs and of uncertain significance, Calvano et al 16 reported similar results for protein-coding mRNAs in circulating leukocytes during endotoxemia. Indeed like Calvano et al, 16 we found in blood that lipopolysaccharide upregulated mRNAs largely reflect the expected innate immune and stress response to endotoxemia, whereas downregulated mRNAs were enriched for genes involved in mitochondrial processes. In adipose, downregulated mRNAs were enriched for distinct metabolic and biosynthetic pathways (not shown). Overall, lipopolysaccharide-induced pathways in blood and adipose converge on inflammatory and stress responses, whereas lipopolysaccharide-suppressed genes and pathways may be more tissue specific incorporating the more specialized functions of these tissues. This is consistent with the concept of energy modulation in response to inflammation in both tissues. 16, 30 One feature of protein-coding genes is evolutionary conservation of functional domains. However, current evidence suggests rapid sequence evolution and an apparent lack of conservation for lincRNAs. Similar to Cabili et al, 8 we found that the subset of lincRNAs present in blood and adipose is much less conserved than protein-coding genes. Indeed, lincRNAs seem to be only slightly more conserved than intergenic non-protein-coding, non-lincRNA regions. However, current whole-genome alignment methods using conservations scores 31 may not detect short conserved functional domains as noted for several functional lincRNAs (eg, Xist, Megamind, and Miat). 7 A subset of lincRNAs demonstrates synteny (conserved neighboring protein-coding genes) without apparent primary sequence conservation, suggesting conserved local cis-regulatory functions, whereas some lincRNA functions may not depend on primary sequence. 5, 7, 8 In our analysis, promoter regions of lipopolysaccharide-modulated lincRNAs in blood were enriched in binding sites for the NFκB family. Thus, despite lack of primary sequence conservation, some lipopolysaccharide-modulated lincRNAs are transcriptional targets of TLR4 canonical signaling increasing the likelihood of specific regulatory functions.
Recently, specific lincRNAs have been implicated in regulation of immune and inflammatory signaling as in vitro. 13, 14 Carpenter et al 13 demonstrated Tlr2 and Tlr4 induction of numerous lincRNAs in mouse bone marrow-derived macrophages and showed that one, lincRNA-Cox2, mediated activation and repression of distinct classes of immune genes via nuclear ribonucleoproteins. Rapicavoli et al 14 identified a set of pseudogene lncRNAs induced by tumor necrosis factor α in an NFκB manner in mouse cells and identified one, Lethe, that functioned in negative feedback signaling to NFκB. Although these rodent lincRNAs are apparently not conserved in human, the pattern of inflammatory lincRNA induction with subsequent negative feedback on inflammatory cascades argues for functional roles for some lipopolysaccharide-modulated lincRNAs.
Our translational studies suggest clinical relevance of lipopolysaccharide-regulated lincRNAs. First, we found that some were expressed differentially in human adipocytes, monocytes, or differentiated/polarized macrophages. This suggests potential functions in cells with prominent roles in cardiometabolic homeostasis. Second, of a small number of adipose lipopolysaccharide-regulated lincRNAs prioritized for follow-up, linc-DMRT2 and linc-TP53I13 were downregulated in adipose of obese humans. Third, although we have yet to establish effects of disease SNPs on lincRNA functions, we did find overlap of lipopolysaccharide-induced lincRNAs with GWAS SNPs for complex inflammatory traits. Linc-CEP110-13 overlaps a SNP (rs10115586) associated with N-glycosylation of circulating immunoglobulin G. Such post-translational glycomic modifications are emerging as mechanistically important in inflammatory and cardiometabolic pathophysiologies. 34, [39] [40] [41] Linc-VWF, induced by lipopolysaccharide and highly expressed in endothelial cells, 8 contains a SNPs (rs1558324) associated with mean platelet volume, 35 a biomarker of platelet function that predicts cardiovascular disease. 36 Linc-VWF is located ≈105 kb from VWF, an endothelial and platelet-derived plasma glycoprotein that plays a central role in hemostasis and thrombosis. 42 There is no linkage disequilibrium between linc-VWF rs1558324 and any SNPs in VWF that have been associated with circulating VWF levels. 37 Functional studies are required to implicate these lincRNAs in SNP-disease association directly. However, it is possible that inflammatory and genetic regulation of specific lincRNAs converge in human inflammatory cardiometabolic disorders.
Our study has several unique strengths and also limitations. This is the first in vivo profiling of blood and adipose lincRNAs during inflammation in human and use an experimental model of proven clinical relevance in cardiometabolic and inflammatory diseases 15-20 that controls temporality limiting spurious findings because of reverse causation or confounding. We applied very deep RNA-seq facilitating identification of lipopolysaccharide modulation of transcripts with low expression, a typical feature of lin-cRNAs. Furthermore, we estimated the depth of coverage requirements and, like others, 6 note that many contemporary studies use sequencing depths that will detect modulation only for very abundant lincRNAs. Although our discovery was limited to one individual, we replicated several specific findings in independent subjects undergoing endotoxemia. Separately, we established broader generalizability of lincRNA expression and lipopolysaccharide modulation through RNA-seq of additional GENE participants. Relative to subject A, a lower proportion of lincRNAs was lipopolysaccharide modulated in the additional subjects, but this is not surprising given the lower RNA-seq depth in additional sequencing and the expected heterogeneity in lipopolysaccharide response across humans 16, 26 ; we note that of lipopolysaccharide-modulated lincRNAs in the additional subjects, ≈80% were also lipopolysaccharide modulated in subject A, suggesting reasonable reproducibility in lipopolysaccharide modulation in blood data. We detected lipopolysaccharide modulation of lincRNAs in PBMCs to a similar degree to that in whole blood, suggesting that modulation of lincRNAs in whole blood is not simply because of change in blood cell composition after lipopolysaccharide. Furthermore, in our large GENE study (≈300 participants), it was impractical in terms of time and cost to separate each cell population in all subjects, while we also have concerns that cell separation can lead to variable degrees of cell activation. We recognize that although our studies in whole blood, PBMCs, and adipose identify transcriptomic events of interest, these findings require cell-specific validation and functional follow-up. Importantly, we did perform preliminary translational experiments in cells and disease tissues and exploited GWAS resources to demonstrate disease relevance.
As evidence for the pervasive nature of human lncRNAs continues to emerge, 5,6 our focus on a stringent set of human lincRNAs 8 may have limited the breadth of discovery. Indeed, in our blood RNA-seq data, we did observe ≈2-fold lipopolysaccharide modulation of MIAT, the ncRNA containing SNPs associated with myocardial infarction in Japanese. 43 However, MIAT was excluded from our lincRNA data set based on its proximity to protein-coding genes. Similarly, ANRIL, also known as CDKN2B-AS1, the lncRNA at the 9p21 vascular disease locus 38 was excluded from our analysis because it overlaps exons of a protein-coding mRNA, CDKN2B. Parenthetically, we retrieved all reads for this 9p21 region in our data sets and found almost no evidence for expression (minimal or absent reads; all FPKM<0.05) of ANRIL exons that did not overlap CDKN2B, suggesting that ANRIL has low expression in blood, PBMCs, and adipose. On balance, in this work, we favor a conservative approach while we pursue RNA-seq studies with larger lincRNAs sets and denovo lincRNA assembly. We acknowledge that our disease associations are preliminary and do not provide evidence for lincRNAs as causal at the locus and require follow-up. Functional validations are ongoing but not trivial and are outside the scope of this report.
Our study provides a unique view of in vivo tissue-specific inflammatory modulation of lincRNAs in humans. We reveal lipopolysaccharide regulation of distinct blood and adipose lincRNAs and provide evidence for roles of specific lincRNAs in cardiometabolic disease. Findings are novel, and our experimental approach has specific potential for clinical and functional translation.
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